Cancer Clinical Trial
Official title:
Refining Information Technology Support for Genetics in Medicine
The clinical use of genetic testing is expanding and, as a result, the number of variants identified in patients is growing. Knowledge of the clinical impact of these variants improves over time. However, the combination of more testing and the rapid evolution of genetic knowledge make it impossible for clinicians to fully account for the latest implications of their patients' genetic profiles as patient care decisions are made. This proposed study plans to enhance and evaluate IT infrastructure developed to provide timely genetic variant updates and patient search functionality to clinicians to assist in optimizing patient care.
A. Specific Aims
Aim 1: To assess the usability of successive versions of our EHR genetic display screens and
variant-based patient search functionality.
Formal usability studies will be conducted with each new release of the GeneInsight Clinic
(GIC) application in order to maximize its effectiveness and efficiency, and user
satisfaction. Results from these studies will be used along with functional and technical
requirements in designing enhancements to each successive version of the software.
Hypothesis: The usability of GeneInsight Clinic and the application's effectiveness,
efficiency, and user satisfaction will improve with each successive version.
Aim 2. To assess the decision-making process associated with issuing alerts relating to new
knowledge on germline variants.
Changes to cardiomyopathy and hearing loss variant level information will be placed in a
queue for evaluation. A board-certified clinical laboratory geneticist will determine which
changes should be released as an "alert" resulting in an update to the GIC and a
notification to the clinician. This decision-making process will be evaluated.
Hypothesis: Evaluation of decision-making regarding release of genetic variant update alerts
will identify patient and physician characteristics, and levels of significance of genetic
variant updates that influence alerting decisions.
Aim 3. To measure the impact on efficiency of new genetic knowledge being incorporated into
clinical care as a result of improved genetic IT infrastructure support.
Currently, clinicians learn of germline genetic variant updates when they choose to call the
genetic laboratories to check for any possible new information on genetic tests of interest.
With the GIC alerting system, treating clinicians will proactively receive genetic variant
updates relevant to their patients. For cancer genotyping tests, once an associated variant
is determined to have clinical significance, treating oncologists are interested in
identifying all their patients with this variant to evaluate whether the patient's care plan
should be modified. With the GIC patient search functionality, treating clinicians will be
able to identify all their patients with the genetic variant of interest.
Hypothesis: The availability of the GIC tool will greatly reduce the time delay associated
with distributing updated variant information to treating clinicians and will reduce the
number of calls the Laboratory of Molecular Medicine (LMM) receives requesting variant
updates. The efficiency of identifying all patients with clinically significant variants
will be improved through use of the PGE tool.
Aim 4: To evaluate the satisfaction of treating clinicians, perceived impact on clinical
care, and net effect on clinician workload associated with deploying genetic infrastructure.
Hypothesis: The introduction and subsequent revisions of the PGE tool will result in
improved satisfaction, a perceived reduction in clinician workload, and a perceived
improvement in clinical care.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
| Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
| Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
| Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
| Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
| Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
| Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
| Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
| Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
| Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
| Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
| Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|